Ivosidenib (AG120)

Phase Ib/II Investigator Initiated Study of the IDH1-Mutant Inhibitor Ivosidenib (AG120) With the BCL2 Inhibitor Venetoclax +/- Azacitidine in IDH1-Mutated Hematologic Malignancies

Near Add Your Location

Center of Excellence

Dana-Farber Cancer Institute
Boston, MA
  • Accepting patients
Case Comprehensive Cancer Center
Case Western Reserve University
Cleveland, OH
  • Accepting patients

Center of Excellence

MD Anderson Cancer Center
The University of Texas
Houston, TX
  • Accepting patients
Oregon Health and Science University
OHSU Knight Cancer Institute
Portland, OR
  • Accepting patients
512 hidden based on your filters. Show All

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.